# Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia

> **NCT03850730** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Cure HHT** · enrollment: 30 (estimated)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia
- Epistaxis

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT03850730
- **Lead sponsor:** Cure HHT
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03850730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03850730, "Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03850730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*